San Diego-primarily based Viking Therapeutics marked itself as a serious competitor in the weight loss drug sector in February immediately after revealing promising info from a mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection As well as in March the